A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Eustace, Amanda Mani, Navin Span, P Irlam, Joely J Taylor, Janet Betts, Guy N J Denley, H Miller, Crispin J Rojas, A Hoskin, P
Eustace, Amanda
Mani, Navin
Span, P
Irlam, Joely J
Taylor, Janet
Betts, Guy N J
Denley, H
Miller, Crispin J
Rojas, A
Hoskin, P
Citations
Altmetric:
Abstract
Tumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefit from hypoxia-modifying treatment in both cancer types.
Authors
Eustace, Amanda
Mani, Navin
Span, P
Irlam, Joely J
Taylor, Janet
Betts, Guy N J
Denley, H
Miller, Crispin J
Rojas, A
Hoskin, P
Buffa, F
Harris, A
Kaanders, J
West, Catharine M L
Mani, Navin
Span, P
Irlam, Joely J
Taylor, Janet
Betts, Guy N J
Denley, H
Miller, Crispin J
Rojas, A
Hoskin, P
Buffa, F
Harris, A
Kaanders, J
West, Catharine M L
Affiliation
Translational Radiobiology Group, Institute of Cancer Sciences, University of Manchester, Christie Hospital, Manchester, United Kingdom.
Description
Date
2013-09-01
Publisher
Collections
Keywords
Type
Article
Citation
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. 2013, 19 (17):4879-88 Clin Cancer Res